Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Moshe Mittelman

Moshe Mittelman

Tel Aviv University
Pre-MDS states: identifying patients at risk and using modern tools to improve prognosis 4:16
Pre-MDS states: identifying patients at risk and using modern tools to improve prognosis
Moshe Mittelman • 5 May 2023
Using cytogenetics to improve the diagnosis and prognosis of MDS & to predict response to treatment 1:41
Using cytogenetics to improve the diagnosis and prognosis of MDS & to predict response to treatment
Moshe Mittelman • 5 May 2023
Lymphoid aggregates as a potential prognostic factor for MDS 3:37
Lymphoid aggregates as a potential prognostic factor for MDS
Moshe Mittelman • 5 May 2023
The role of inflammation in MDS & the potential to target it to prevent and treat MDS 3:39
The role of inflammation in MDS & the potential to target it to prevent and treat MDS
Moshe Mittelman • 5 May 2023
Validation of non-invasive AI diagnostic tool for MDS 5:55
Validation of non-invasive AI diagnostic tool for MDS
Moshe Mittelman • 5 May 2023
Promising agents under investigation for low and high-risk MDS 3:46
Promising agents under investigation for low and high-risk MDS
Moshe Mittelman • 12 Dec 2022
Managing transfusion dependence in MDS: lenalidomide, ESAs & defining a threshold for transfusion 3:46
Managing transfusion dependence in MDS: lenalidomide, ESAs & defining a threshold for transfusion
Moshe Mittelman • 12 Dec 2022
Incorporating genetic analyses in the diagnostic pathway of MDS 1:18
Incorporating genetic analyses in the diagnostic pathway of MDS
Moshe Mittelman • 12 Dec 2022
Machine learning-based predictive model to identify individuals at risk to develop multiple myeloma 3:00
Machine learning-based predictive model to identify individuals at risk to develop multiple myeloma
Moshe Mittelman • 12 Dec 2022
Classification of high-risk mutations in MDS 10:18
Classification of high-risk mutations in MDS
Moshe Mittelman • 13 Sep 2021
MDS: the direction the field is headed 12:00
MDS: the direction the field is headed
Moshe Mittelman • 13 Sep 2021
Key themes from MDS 2020 2:10
Key themes from MDS 2020
Moshe Mittelman • 5 Mar 2020
Role of hypomethylating agents in the novel agent era 1:02
Role of hypomethylating agents in the novel agent era
Moshe Mittelman • 5 Mar 2020
Pevonedistat with azacitidine for high-risk MDS 1:47
Pevonedistat with azacitidine for high-risk MDS
Moshe Mittelman • 5 Mar 2020
Progress in the MDS field 2:05
Progress in the MDS field
Moshe Mittelman • 5 Mar 2020
Ineffective erythropoiesis in MDS 3:34
Ineffective erythropoiesis in MDS
Moshe Mittelman • 5 Mar 2020
The content of VJHemOnc is intended for healthcare professionals